Keloid Scarring: Treatment and Pathophysiology
Phase 4
Withdrawn
- Conditions
- Keloid Scar
- Interventions
- Registration Number
- NCT01295099
- Lead Sponsor
- Queen Mary University of London
- Brief Summary
To clarify the mechanisms of Keloid scar formation.
Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment
Identify the genetic link with Keloid scar formation.
Quantify the psychological/social impact in keloid scarring patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Adult ( > 18 years old).
- Keloid scarring present.
- Able to understand and give informed consent.
- Patients giving informed consent to donate keloidal or non-affected skin when that is redundant after a procedure (i.e. BBR, Abdominoplasty).
- Patients with a strong familial pedigree of keloid scar formation.
Exclusion Criteria
-
Open wound at or proximity of the lesion
- Infected lesion
- Pregnant or planning pregnancy in the near future
- Lactating (Breast Feeding)
- Abnormal renal or liver function tests
- Atrophic scars
- Patient under 18 years of age
- Immunocompromised
- OR immunosuppressed
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Radiotherapy radiotherapy Large keloid scars undergo extralesional excision and radiotherapy 5-Fluorouracil 5- fluorouracil Patients with small keloidal scars to have intralesional 5FU injected TAC Triamcinolone -
- Primary Outcome Measures
Name Time Method Keloid Scar Reduction 18 months Using a 3D scanner to observe the reduction of the scar volume measured in cubic centimetres
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Barts and the London NHS Trust
🇬🇧London, UK, United Kingdom